Entity

Time filter

Source Type

Dixon Lane-Meadow Creek, CA, United States

Kozocas J.A.,SRI International | Bupp J.E.,SRI International | Tanga M.J.,SRI International | Pluhar J.T.,Moravek Biochemicals Inc. | Wainer I.W.,U.S. National Institute on Aging
Journal of Labelled Compounds and Radiopharmaceuticals | Year: 2010

The preparation of 2′,4′,6′-[3H 3]-(R,R)-4-methoxyfenoterol, a tritium-labeled derivative of (R,R)-4-methoxyfenoterol was demonstrated on a 15 mCi scale providing material with a specific activity of 57 Ci/mmol. Copyright © 2009 John Wiley & Sons, Ltd. Source


Latli B.,Boehringer Ingelheim Pharmaceuticals | Hrapchak M.,Boehringer Ingelheim Pharmaceuticals | Switek H.-K.,Boehringer Ingelheim | Retz D.M.,Moravek Biochemicals Inc. | And 2 more authors.
Journal of Labelled Compounds and Radiopharmaceuticals | Year: 2010

Ambroxol is a mucolytic agent used in the treatment of respiratory diseases. Herein, we report the synthesis of carbon-14-labeled ambroxol with the radioactive atom(s) either on the benzylic carbon or uniformly in the cyclohexyl ring with specific activities of 59 and 81 mCi/mmol, respectively. We also describe the preparation of deuterium-labeled ambroxol, its deuterium-labeled tetrahydroquinazoline metabolite (DHTQ), carbon-13-labeled 3,5-dibromoanthranilic acid metabolite, as well as an unlabeled O-glucuronide conjugate. Copyright © 2009 John Wiley & Sons, Ltd. Source


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 539.75K | Year: 1995

N/A


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 48.00K | Year: 1991

THE GOAL OF THIS PROJECT IS TO MAINTAIN AND OPERATE A SPECIALIZED LABORATORY FOR THE SYNTHESIS OF SELECTED ANTI-CANCER AND ANTI-AIDS COMPOUNDS LABELED WITH CARBON-14, TRITIUM OR SULFUR-35. IN ADDITION, WE WILL DEVELOP THE RADIOSYNTHESIS OF SUCH DRUGS SELECTED BY NCI. THE LABEL WILL BE INCORPORATED AT A DESIRABLE SITE OF THE MOLECULE BY A CAREFULLY SELECTED SYNTHETIC SEQUENCE OR BY A SUITABLE EXCHANGE PROCEDURE. EFFORTS WILL CONCENTRATE ON FINDING OPTIMAL CONDITIONS FOR SUCH LABELING IN NON-RADIOACTIVE AND/OR TRACER EXPERIMENTS. THE OPTIMUM REACTION CONDITIONS WILL THEN BE APPLIED TO THE SYNTHESIS OF RADIOACTIVE MATERIALS ON A PREPARATIVE SCALE. SPECIAL ATTENTION WILL BE PAID TO THE ACHIEVEMENT OF HIGH MOLAR SPECIFIC RADIOACTIVITY AND CHEMICAL AND RADIOCHEMICAL PURITY (>98%). WE WILL MAINTAIN COMPLETE DATA SHEETS AND RECORDS OF DETAILED LABORATORY PROCEDURES OR INDIVIDUAL PRODUCTS. ALL COMPOUNDS WILL BE STORED AT CONDITIONS MOST SUITABLE FOR EACH PRODUCT, INCLUDING STORAGE IN RADIOLYSIS PREVENTING SOLVENTS AND STORAGE AT -80O IN A FREEZER DEDICATED TO THIS PROJECT. SPECIFIC AMOUNTS OF RADIOLABELED COMPOUNDS SYNTHESIZED IN THIS PROJECT, WILL BE SHIPPED BY FEDERAL EXPRESS TO DESIGNATED INVESTIGATORS. PACKAGING AND SHIPPING WILL COMPLY WITH THE REGULATIONS OF THE U. S. DEPARTMENT OF TRANSPORTATION.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 50.00K | Year: 1991

N/A

Discover hidden collaborations